Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Yes, insomnia is one of the more common early side effects
Acute Sports Injuries: Tendon and ligament sprains, muscle tears, and overuse injuries respond well to peptide therapy
New studies continue to explore cardiovascular benefits, effects on fatty liver disease, and potential applications beyond weight loss
Contents: 10mg of BPC-157 Form : Lyophilized Powder Emerging Research Evidence: Studied for tissue-repair signaling , structural support pathways , cellular resilience , and multi-tissue response markers in pre-clinical research
Peptides that are currently difficult to detect may have established methods within years
US$ 27.89
US$ 27.52
US$ 28.41
